Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02779049
Other study ID # 201407079RIND
Secondary ID
Status Completed
Phase N/A
First received May 18, 2016
Last updated December 13, 2016
Start date January 2015
Est. completion date July 2016

Study information

Verified date December 2016
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Ministry of Health and Welfare
Study type Observational

Clinical Trial Summary

1. To understand the components of PBMC in MAC-LD patients, including T cells, B cells, nature killer cells, and monocyte.

2. To confirm the phenomenon of reduced PBMC response in MAC-LD patients

3. To study the proportion of apoptosis and PD-1 expression in T cells among MAC-LD patients, MAC colonizers, patients with tuberculosis, and healthy controls.

4. To study the apoptosis and PD-1/PD-L1 expression in T cells/macrophage from bronchial lavage among MAC-LD patients, MAC colonizers, patients with tuberculosis,

5. To examine the PD-1 gene polymorphism and the correlation with MAC-LD.


Description:

Read more »
Read more »

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
Blood examination
blood sampling

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of disease progression 2 year No
See also
  Status Clinical Trial Phase
Recruiting NCT06266442 - M. Avium WGS During Mav-PD Treatment